Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Ekol Hospitals leads in shaping the future of Obesity TreatmentEkol International Hospitals, a leading authority in obesity treatment in Türkiye, underscores the urgent need for a holistic and ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors. (Image Credits: Pixabay) It has been a year since the launch of Zepbound (tirzepatide) for obesity ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...